

**BioSyent Inc.**

# **Interim Unaudited Condensed Consolidated Financial Statements**

**For the three and nine months ended  
September 30, 2021 and 2020**

**November 18, 2021**

Corporate Office  
Suite 402  
2476 Argentia Road  
Mississauga, Ontario, L5N 6M1  
Canada

Telephone 905.206.0013  
Facsimile 905.206.1413  
Email: [info@biosyent.com](mailto:info@biosyent.com)  
Web: [www.biosyent.com](http://www.biosyent.com)



# Management's Responsibility For Financial Reporting

To the Shareholders of BioSyent Inc.:

Management has prepared the interim unaudited condensed consolidated financial statements for BioSyent Inc. (the "**Company**") in accordance with National Instrument 51-102 – *Continuous Disclosure Obligations* released by the Canadian Securities Administration. The Company discloses that its auditors have not reviewed these interim unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2021 and 2020.



Robert J. March

Vice-President and Chief Financial Officer, BioSyent Inc.

November 18, 2021

**BioSyent Inc.**  
**Interim Unaudited Condensed Consolidated Statements of Financial Position**

(Expressed in Canadian Dollars)

AS AT	September 30, 2021	December 31, 2020
<b>ASSETS</b>		
Cash and cash equivalents (Note 6)	\$18,790,615	\$20,291,421
Short term investments (Note 7)	8,311,318	5,286,285
Trade and other receivables (Note 8)	3,742,588	1,815,015
Inventory (Note 9)	2,469,958	2,073,561
Prepaid expenses and deposits	479,810	307,599
Loans receivable - current (Note 13)	419,056	-
<b>CURRENT ASSETS</b>	<b>34,213,345</b>	<b>29,773,881</b>
Property and equipment (Note 11)	1,967,747	2,161,698
Intangible assets (Note 12)	895,437	1,007,822
Loans receivable - non current (Note 13)	182,744	597,332
Deferred tax asset	66,058	30,481
<b>TOTAL NON CURRENT ASSETS</b>	<b>3,111,986</b>	<b>3,797,333</b>
<b>TOTAL ASSETS</b>	<b>\$37,325,331</b>	<b>\$33,571,214</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
Accounts payable and accrued liabilities	\$4,726,526	\$3,723,486
Contract liability (Note 14)	232,817	246,124
Customer advances	237,970	688,312
Lease liability - current (Note 15)	158,401	151,949
Derivative liability (Note 10)	5,961	78,608
Income tax payable	69,135	250,195
<b>CURRENT LIABILITIES</b>	<b>5,430,810</b>	<b>5,138,674</b>
Deferred tax liability	125,064	79,672
Lease liability - non current (Note 15)	1,437,067	1,556,912
<b>TOTAL NON CURRENT LIABILITIES</b>	<b>1,562,131</b>	<b>1,636,584</b>
Share capital (Note 16)	5,841,734	6,392,428
Contributed surplus	1,732,527	1,494,419
Cumulative translation adjustment	(198,630)	(166,705)
Retained earnings	22,956,759	19,075,814
<b>TOTAL EQUITY</b>	<b>30,332,390</b>	<b>26,795,956</b>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b>\$37,325,331</b>	<b>\$33,571,214</b>

Contingencies (Note 19)

Commitments (Note 20)

Related party transactions (Note 21)

APPROVED ON BEHALF OF THE BOARD



René Goehrum

DIRECTOR

November 18, 2021



Peter Lockhard

DIRECTOR

November 18, 2021

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

**BioSynt Inc.**
**Interim Unaudited Condensed Consolidated Statements of Net Income and Comprehensive Income**

(Expressed in Canadian Dollars)

	For the three months ended September 30,		For the nine months ended September 30,	
	2021	2020	2021	2020
Net revenues from contracts with customers (Note 25)	\$6,690,419	\$5,771,739	\$21,399,562	\$16,605,840
Cost of goods sold (Notes 9, 17)	1,433,239	1,277,645	4,583,301	3,581,708
Gross profit	5,257,180	4,494,094	16,816,261	13,024,132
Selling, general and administration expenses (Note 17)	3,054,198	3,219,833	10,950,982	8,918,524
New business development costs (Note 17)	13,570	30,143	67,911	59,010
Operating profit	2,189,412	1,244,118	5,797,368	4,046,598
Finance costs (Notes 15, 17)	21,248	23,134	64,503	70,286
Finance income (Note 17)	(31,434)	(81,566)	(99,018)	(224,537)
<b>NET INCOME BEFORE TAXES</b>	<b>2,199,598</b>	<b>1,302,550</b>	<b>5,831,883</b>	<b>4,200,849</b>
Current income tax	445,594	279,686	1,418,156	1,019,210
Deferred tax expense	32,684	66,955	9,965	52,006
<b>NET INCOME AFTER TAXES</b>	<b>1,721,320</b>	<b>955,909</b>	<b>4,403,762</b>	<b>3,129,633</b>
<b>OTHER COMPREHENSIVE INCOME</b>				
Currency translation gains (losses)	61,019	2,110	(31,925)	(29,352)
<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD</b>	<b>\$1,782,339</b>	<b>\$958,019</b>	<b>\$4,371,837</b>	<b>\$3,100,281</b>
Basic weighted average number of shares outstanding (Note 18)	12,669,586	12,808,287	12,730,752	13,061,099
Basic earnings per share (Note 18)	\$0.136	\$0.075	\$0.346	\$0.240
Diluted weighted average number of shares outstanding (Note 18)	12,851,984	12,938,844	12,913,296	13,180,155
Diluted earnings per share (Note 18)	\$0.134	\$0.074	\$0.341	\$0.237

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

**BioSynt Inc.**
**Interim Unaudited Condensed Consolidated Statements of Cash Flows**

(Expressed in Canadian Dollars)

	For the nine months ended September 30,	
	2021	2020
<b>OPERATING ACTIVITIES</b>		
Net income after taxes	\$4,403,762	\$3,129,633
<b>Items not affecting cash:</b>		
Depreciation - property and equipment (Notes 11, 17)	230,738	250,171
Amortization - intangible assets (Notes 12, 17)	116,475	146,871
Share-based payments (Note 16)	246,104	195,987
Change in derivative liability (Note 10)	(72,647)	(64,261)
Net finance income	(34,515)	(154,251)
Loan interest receivable (Note 13)	(4,468)	(8,835)
Deferred tax recovery	9,965	52,006
<b>Net change in non-cash working capital items:</b>		
Trade and other receivables	(1,964,590)	(534,519)
Inventory	(396,397)	891,766
Prepaid expenses and deposits	(172,211)	120,840
Accounts payable and accrued liabilities	1,003,040	(102,422)
Contract liability	(13,307)	65,180
Customer advances	(450,342)	-
Income tax payable	(181,060)	891,786
<b>Cash provided by operating activities</b>	<b>2,720,547</b>	<b>4,879,952</b>
<b>INVESTING ACTIVITIES</b>		
Additions to property and equipment (Note 11)	(36,787)	(9,419)
Additions to intangible assets (Note 12)	(4,090)	(34,496)
(Increase) decrease in short term investments (Note 7)	(3,025,033)	2,987,692
Interest received	135,885	224,536
<b>Cash (used in) provided by investing activities</b>	<b>(2,930,025)</b>	<b>3,168,313</b>
<b>FINANCING ACTIVITIES</b>		
Payments - lease liability principal (Note 15)	(113,393)	(107,610)
Payments - lease liability interest (Note 15)	(64,503)	(70,286)
Repurchase of common shares - NCIB (Note 16)	(562,418)	(2,663,260)
Purchase of RSU Plan shares - held in trust (Note 16)	(527,179)	(463,807)
Proceeds from stock options exercised	8,090	2,666
<b>Cash used in financing activities</b>	<b>(1,259,403)</b>	<b>(3,302,297)</b>
<b>Effect of foreign currency translation adjustment</b>	<b>(31,925)</b>	<b>(29,352)</b>
<b>INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>(1,500,806)</b>	<b>4,716,616</b>
Cash and cash equivalents, beginning of period	20,291,421	13,441,817
<b>CASH AND CASH EQUIVALENTS - END OF PERIOD</b>	<b>\$18,790,615</b>	<b>\$18,158,433</b>
<i>SUPPLEMENTARY DISCLOSURE:</i>		
<b>NET CHANGE IN CASH AND SHORT TERM INVESTMENTS</b>		
Cash and short term investments, beginning of period	\$25,577,706	\$21,973,477
Increase (decrease) in short term investments	3,025,033	(2,987,692)
Increase (decrease) in cash and cash equivalents	(1,500,806)	4,716,616
<b>CASH AND SHORT TERM INVESTMENTS - END OF PERIOD</b>	<b>\$27,101,933</b>	<b>\$23,702,401</b>
<b>CASH PAID FOR TAXES</b>	<b>\$(1,599,215)</b>	<b>\$(1,019,210)</b>

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

**BIOSYENT INC.****Interim Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity**

(Expressed in Canadian Dollars)

	Share Capital	Contributed Surplus	Cumulative Currency Translation Adjustment	Retained Earnings	Total Shareholders' Equity
<b>Balance as of January 1, 2021</b>	\$ 6,392,428	\$ 1,494,419	\$ (166,705)	\$ 19,075,814	\$ 26,795,956
Comprehensive Income for the period	-	-	(31,925)	4,403,762	4,371,837
Common shares repurchased under Normal Course Issuer Bid (Note 16)	(39,601)	-	-	(522,817)	(562,418)
Common shares purchased and held in RSU Plan Trust (Note 16)	(527,179)	-	-	-	(527,179)
Effect of Share-based payments: Options vested (Note 16)	-	58,200	-	-	58,200
Effect of Share-based payments: Options exercised (Note 16)	16,086	(7,996)	-	-	8,090
Effect of Share-based payments: RSU expense (Note 16)	-	187,904	-	-	187,904
<b>Balance as of September 30, 2021</b>	\$ 5,841,734	\$ 1,732,527	\$ (198,630)	\$ 22,956,759	\$ 30,332,390

	Share Capital	Contributed Surplus	Cumulative Currency Translation Adjustment	Retained Earnings	Total Shareholders' Equity
<b>Balance as of January 1, 2020</b>	\$ 7,179,617	\$ 1,235,549	\$ (105,300)	\$ 17,484,644	\$ 25,794,510
Comprehensive Income for the period	-	-	(29,352)	3,129,633	3,100,281
Common shares repurchased under Normal Course Issuer Bid (Note 16)	(305,588)	-	-	(2,204,165)	(2,509,753)
Common shares purchased and held in RSU Plan Trust (Note 16)	(463,807)	-	-	-	(463,807)
Effect of Share-based payments: Options vested (Note 16)	-	122,083	-	-	122,083
Effect of Share-based payments: Options exercised (Note 16)	5,291	(2,625)	-	-	2,666
Effect of Share-based payments: RSU Expense (Note 16)	-	73,904	-	-	73,904
<b>Balance as of September 30, 2020</b>	\$ 6,415,513	\$ 1,428,911	\$ (134,652)	\$ 18,410,112	\$ 26,119,884

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

## 1. General Information

BioSyent Inc. (“**BioSyent**” or the “**Company**”), is a publicly traded specialty pharmaceutical company which, through its wholly-owned subsidiaries, BioSyent Pharma Inc. (“**BioSyent Pharma**”) and BioSyent Pharma International Inc., acquires or licences and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly-owned subsidiary of BioSyent, operates the Company’s legacy business marketing biologically and health friendly non-chemical insecticides. BioSyent’s common shares (the “**Common Shares**”) are listed for trading on the TSX Venture Exchange under the symbol “RX”.

The accompanying interim unaudited condensed consolidated financial statements (the “**Financial Statements**”) of BioSyent include the accounts of BioSyent Inc. and its four wholly-owned subsidiaries: BioSyent Pharma Inc., BioSyent Pharma International Inc., Hedley Technologies Ltd., and Hedley Technologies (USA) Inc. (“**Hedley USA**”).

The Company changed its name from “Hedley Technologies Inc.” to “BioSyent Inc.” on June 13, 2006 to reflect the Company’s forward focus on the pharmaceutical market. BioSyent Pharma was incorporated on April 6, 2006 under the Canada Business Corporations Act and commenced operations in 2006. Hedley Technologies Ltd. was incorporated on January 30, 1996 in the province of British Columbia, Canada. Hedley USA was incorporated on May 13, 1994 in the state of Washington, USA. BioSyent Pharma International Inc. was incorporated on April 18, 2016 in Barbados.

BioSyent’s principal place of business is located at 2476 Argentia Road, Suite 402, Mississauga, Ontario, Canada L5N 6M1.

These Financial Statements were approved by the Board of Directors on November 18, 2021.

## 2. Basis of Presentation

The principal accounting policies adopted in the preparation of these Financial Statements on a historical cost basis, with the exception of those financial assets and liabilities at fair value through profit or loss (“**FVTPL**”), are set out below. The policies have been consistently applied to all the periods presented.

Certain amounts in the prior period have been reclassified to conform with the presentation of the current period financial statements. These reclassifications had no effect on the reported results of operations.

### Statement of Compliance

These Financial Statements are in compliance with International Accounting Standard 34, “Interim Financial Reporting” (“**IAS 34**”). Accordingly, certain information and disclosures normally included in annual financial statements prepared in accordance with International Financial Reporting Standards (“**IFRS**”), as issued by the International Accounting Standards Board (“**IASB**”) have been omitted or condensed.

Since these Financial Statements do not include all disclosures required by IFRS for annual financial statements, they should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2020.

### Basis of Consolidation

All inter-company transactions have been eliminated in these Financial Statements.

### Functional and Presentation Currency

The presentation currency of these Financial Statements is the Canadian dollar (“**CAD**”). The functional currency of the Company and two of its subsidiaries, BioSyent Pharma and Hedley Technologies Ltd., is the Canadian dollar. The functional currency of Hedley USA and BioSyent Pharma International Inc. is the U.S. dollar (“**USD**”).

All financial information has been rounded to the nearest dollar except where otherwise indicated.

## 3. Summary of Significant Accounting Policies

The accounting policies adopted in the preparation of these Financial Statements are consistent with those followed in the preparation of the Company’s consolidated financial statements for the year ended December 31, 2020.

### Accounting Pronouncements Issued but not yet Effective

The Company has not early adopted any standards, interpretations or amendments that have been issued but are not yet effective.

#### 4. Use of Estimates and Accounting Judgments by Management

There have been no material revisions to the nature and amount of changes in estimates of amounts reported in the Company's consolidated financial statements for the year ended December 31, 2020.

#### 5. COVID-19

On March 11, 2020, the World Health Organization characterized COVID-19 (Coronavirus) as a pandemic. The COVID-19 pandemic has impacted and is likely to continue to impact the Company's operations in the following key areas:

a. Workforce:

The Company will continue to follow the recommendations of public health and government authorities and to take all necessary precautions, including remote work arrangements, the ongoing practice of physical distancing, making personal protective equipment available to employees, and ensuring employees' understanding of good hygiene practices and infection risks, in order to protect the health and safety of its workforce, both in its head office and in the field.

b. Access to Healthcare Professionals:

COVID-19 restrictions have affected the ability of the Company's field salesforce to access healthcare professionals in the community and in hospitals for the purposes of product detailing. While the extent and duration of such access restrictions varies by region in Canada, such restrictions may have an impact on the Company's Canadian pharmaceutical sales during the time they are in place.

c. Demand for Products:

To the extent that the COVID-19 pandemic affects patient volumes (both in community clinics and in hospitals) and the nature of procedures performed in Canadian hospitals, this will

affect the consumption of the Company's non-prescription products, prescription products, urgent care products as well as its hospital products used in elective procedures.

Additionally, to the extent that the COVID-19 pandemic and safety restrictions affect consumer buying behaviour, this will affect demand for the Company's pharmaceutical products in the community. The extent of the impact of COVID-19 on consumer demand for the Company's products in the short-term and long-term is uncertain.

Finally, given the global scale of COVID-19, demand for the Company's products in international markets may also be affected, depending on the extent of local infection rates, the measures implemented by local governments in response, and the overall impact of the pandemic on business activity in these international markets.

d. Supply Chain:

The Company sources its products globally. Given the global impact of the COVID-19 pandemic and varying localized impacts, this could result in interruptions to the Company's supply chains, including the manufacturing, transportation, and delivery of products to customers.

#### 6. Cash and Cash Equivalents

Cash and cash equivalents consist of the following:

	September 30, 2021	December 31, 2020
Cash on deposit in banks	\$14,901,199	\$10,326,877
Redeemable GICs	3,889,416	9,964,544
Total cash and cash equivalents	\$18,790,615	\$20,291,421

#### 7. Short term Investments

Short term investments consist of the following:

	September 30, 2021	December 31, 2020
Non-redeemable GICs	\$6,044,166	\$4,043,968
Dual Currency Deposits (Note 10)	2,267,152	1,242,317
Total short term investments	\$8,311,318	\$5,286,285



## 8. Trade and Other Receivables

Trade and other receivables are summarized as follows:

	September 30, 2021	December 31, 2020
Trade accounts receivable (Note 10)	\$3,497,874	\$1,599,028
Other receivables	244,714	215,987
Total trade and other receivables	\$3,742,588	\$1,815,015

## 9. Inventory

Inventory is comprised of the following:

	September 30, 2021	December 31, 2020
Raw and Packaging Materials	\$631,516	\$366,757
Finished Goods	1,838,442	1,706,804
Total inventory	\$2,469,958	\$2,073,561

Cost of goods sold is comprised of the following:

	Three months ended	
	September 30, 2021	September 30, 2020
Raw and Packaging Materials and Finished Goods	\$1,394,772	\$1,246,376
Freight	38,467	31,269
Total cost of goods sold	\$1,433,239	\$1,277,645

	Nine months ended	
	September 30, 2021	September 30, 2020
Raw and Packaging Materials and Finished Goods	\$4,461,770	\$3,462,776
Freight	121,531	118,932
Total cost of goods sold	\$4,583,301	\$3,581,708

## 10. Financial Instruments and Financial Risk Management

### Fair Value Measurement

#### Fair Value Estimation of Financial Instruments

The carrying value of the Company's cash and cash equivalents, short term investments, derivative assets/liabilities, trade and other receivables, loans receivable, and accounts payable and accrued liabilities approximate their fair values.

#### Risks

The Company is exposed to a variety of financial risks by virtue of its activities: market risk (including foreign exchange risk, interest rate risk, and credit risk) and liquidity risk. The overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on financial performance. Risk management is carried out under the policies described below. Management is charged with the responsibility of establishing controls and procedures to ensure that financial risks are mitigated with the approved policies.

#### ➤ Foreign Exchange Instruments:

The Company periodically enters into foreign exchange options and forward contracts with financial institutions with investment grade credit ratings to manage its foreign exchange risk on contracts denominated in U.S. dollars and Euros. Such instruments are classified as derivative financial instruments and measured at fair value through profit and loss.

#### Options:

The Company had not entered into any foreign exchange options as at September 30, 2021.

As at December 31, 2020, the Company entered into foreign exchange options to purchase up to a total of USD 900,000 and USD 1,350,000 at an exchange rate expressed in CAD per USD of 1.3100.

**Forward Contracts:**

As at September 30, 2021, the Company entered into a foreign exchange forward contract to purchase a total of USD 100,000 (December 31, 2020 – USD 650,000) at an exchange rate expressed in CAD per USD of 1.3215 which will be settled on October 1, 2021.

As at December 31, 2020, the Company entered into foreign exchange forward contracts to purchase a total of EUR 450,000.

The fair value of foreign exchange instruments is estimated based on quoted values from financial institutions. The Company's foreign exchange instruments resulted in a derivative liability of \$5,961 as at September 30, 2021 (December 31, 2020 – \$78,608).

The following table illustrates the Company's investment in foreign exchange instruments that are measured at FVTPL:

September 30, 2021	Level 1	Level 2	Level 3
Foreign Exchange Instruments	-	(\$5,961)	-

December 31, 2020	Level 1	Level 2	Level 3
Foreign Exchange Instruments	-	(\$78,608)	-

**➤ Dual Currency Deposits:**

The Company also invests in dual currency deposits (“DCD”). A DCD is a CAD or foreign currency denominated transaction that provides an enhanced guaranteed interest payment at maturity. However, the original denominated currency is converted to another specified currency at a specified exchange rate depending

on whether the spot rate on the maturity date is above or below a specified fixed exchange rate. The fair value of DCDs is estimated based on quoted values from financial institutions.

The following table illustrates the Company's investment in DCDs measured at fair value through profit and loss:

September 30, 2021	Level 1	Level 2	Level 3
DCDs	-	\$2,267,152	-

December 31, 2020	Level 1	Level 2	Level 3
DCDs	-	\$1,242,317	-

At September 30, 2021, the Company had the following CAD denominated DCD that was convertible into USD:

Type of Financial Instrument	Spot Rate on Transaction Date	Principal (CAD)	Net Fair Value (CAD)	Guaranteed Interest Rate	Maturity Date	Fixed Maturity Conversion Rate
DCD	1.2662	\$1,000,000	\$995,966	1.69%	December 13, 2021	1.2400

At September 30, 2021, the Company had the following USD denominated DCDs that were convertible into CAD:

Type of Financial Instrument	Spot Rate on Transaction Date	Principal (USD)	Net Fair Value (CAD)	Guaranteed Interest Rate	Maturity Date	Fixed Maturity Conversion Rate
DCD	1.2589	\$500,000	\$636,442	1.13%	October 21, 2021	1.3000
DCD	1.2721	\$500,000	\$634,744	1.43%	December 17, 2021	1.3100

At December 31, 2020, the Company had the following CAD denominated DCD that was convertible into USD:

Type of Financial Instrument	Spot Rate on Transaction Date	Principal (CAD)	Net Fair Value (CAD)	Guaranteed Interest Rate	Maturity Date	Fixed Maturity Conversion Rate
DCD	1.2965	\$1,250,000	\$1,242,317	3.26%	January 4, 2021	1.2850

The fair value of dual currency deposits is estimated based on quoted values from financial institutions.

**➤ Foreign Exchange Risk:**

The Company currently earns revenue in Canadian dollars, U.S. dollars and Euros and incurs costs in Canadian dollars, U.S. dollars and Euros. Management monitors the foreign currency net liability position on an ongoing basis during the period and adjusts the total net monetary liability balance accordingly. When it

is appropriate to de-risk future foreign exchange transactions, the Company uses foreign exchange options, forward contracts, and DCDs to manage foreign exchange transaction exposure.

The following tables present foreign exchange sensitivity analyses for the assets and liabilities of the Company denominated in foreign currencies:

#### Foreign Exchange Sensitivity Analysis - USD

Description of Asset/(Liability)	September 30, 2021	December 31, 2020
	USD	USD
Cash and cash equivalents	1,808,857	1,551,272
Short term investments	999,832	975,744
Trade receivables	69,102	17,292
Less: Accounts payable	(603,822)	
Less: Customer advances	(178,200)	(591,928)
Net Total	2,095,769	1,952,380
Foreign Exchange Rate CAD per USD at the end of the period	1.2741	1.2732

At September 30, 2021, if the U.S. dollar had been stronger or weaker by 10% against the Canadian dollar with all other variables held constant, comprehensive income would have been \$252,807 higher or lower on an after-tax basis, respectively (December 31, 2020 - \$182,704 higher or lower, respectively).

#### Foreign Exchange Sensitivity Analysis - EUR

Description of Asset/(Liability)	September 30, 2021	December 31, 2020
	EUR	EUR
Cash and cash equivalents	635,518	743,512
Less: Customer deposits	-	(441,000)
Less: Accounts payable	(320,811)	(85,563)
Net Total	314,707	216,949
Foreign Exchange Rate CAD per EUR at the end of the period	1.4801	1.5608

At September 30, 2021, if the Euro had been stronger or weaker by 10% against the Canadian dollar with all other variables held constant, comprehensive income would have been \$34,236 higher or lower on an after-tax basis, respectively (December 31, 2020 - \$25,877 higher or lower, respectively).

#### ➤ Interest Rate Risk:

Cash flow interest rate risk is the risk that the future cash flow of a financial instrument will fluctuate because of changes in interest rates. Some of the Company's cash and cash equivalents as at the date of the Company's Consolidated Statements of Financial Position are invested in redeemable guaranteed investment certificates (each, a "GIC"), which earn interest at fixed rates during their tenure. The Company's short-term investments consist of non-redeemable GICs which also earn interest at fixed rates during their tenure. These GICs all have terms of one year or less.

The Company manages its interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct operations on a day-to-day basis.

Fluctuations in market rates of interest when these GICs are renewed may have an impact on the Company's Finance Income for the period.

#### ➤ Credit Risk:

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's cash and cash equivalents, short term investments, trade and other receivables, and loans receivable. The carrying amount of financial assets represents maximum credit exposure. As the Company invests in GICs with Canadian Chartered Banks, its credit risk on this account is negligible. The Company's loans receivable (*see Note 13*) are full recourse and secured by a pledge of common shares of the Company purchased by the Borrowers, who are key management personnel. Based on these factors, the Company considers the credit risk associated with these loans receivable to be low. There are no factors at the end of the period to indicate a significant increase in credit risk has occurred and there are no defaults on the loans receivable.

The majority of the Company's current customers are corporations with whom the Company has transacted for several years. In assessing the credit risk of its trade accounts receivable, the Company considers historical default rates and payment patterns, the nature of its customer base, and forward-looking information including any anticipated changes to its customer base, credit terms, and pricing.

Aged Trade Accounts Receivable	September 30, 2021	December 31, 2020
Current	\$ 2,839,380	\$ 1,444,432
Past due 1-30 days	561,626	110,964
Past due 31-60 days	30	22,783
Past due over 60 days	149,849	87,559
Expected credit loss	(53,011)	(66,710)
Closing Balance (Note 8)	\$ 3,497,874	\$ 1,599,028
Maximum Credit Risk	3,550,885	1,665,738

As of September 30, 2021, one customer represents 38% of trade receivables (December 31, 2020 - 43%) while another customer represents 17% of trade receivables (December 31, 2020 - 4%), a third customer represents 14% of trade receivables (December 31, 2020 - 19%), and a fourth customer represents 10% of trade receivables (December 31, 2020 - 15%). There have been no past credit losses from these customers.

The Company has provided for expected credit losses of \$53,011 (December 31, 2020 - \$66,710) related to certain disputed deductions on trade receivables by certain Canadian pharmaceutical wholesale customers. During the nine months ended September 30, 2021, the Company recovered \$13,699 of previously recorded expected credit losses on accounts receivable.

Cash, cash equivalents and short-term investments are maintained with Canadian financial institutions and the wholly owned subsidiaries of these financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions of reputable credit and therefore bear minimal credit risk.

➤ **Liquidity Risk:**

Liquidity risk is the risk that the Company will not be able to meet its obligations as they fall due. The Company manages its liquidity risk by forecasting cash flows from operations and anticipated investing and financing activities. Senior management is actively involved in the review and approval of planned expenditures. All contractual maturities of accounts payable and accrued liabilities are due within one year. The Company has no other financial liabilities not carried at fair value.

The Company generates sufficient cash from operating activities to fund its operations and fulfill its obligations as they become due. The Company has credit facilities available with Royal Bank of Canada totalling \$3,090,000, including a revolving demand credit

facility of \$1,500,000 which it has not drawn down as at the date hereof, a foreign exchange facility of \$1,500,000, and credit card facilities totalling \$90,000.

There were no changes to the Company's exposure to liquidity risk, credit risk, or interest rate risk or to its approach to managing these risks during the period ended September 30, 2021.

## 11. Property and equipment

	Furniture and Fixtures	Equipment	Computer Equipment	Computer Software	Right-of-Use Asset (see Note 15)	Leasehold Improvements	Total
<b>COST:</b>							
December 31, 2019	\$250,060	\$220,078	\$266,764	\$371,065	\$1,330,455	\$680,511	\$3,118,933
2020 Additions	4,879	-	8,739	-	-	-	13,618
December 31, 2020	\$254,939	\$220,078	\$275,503	\$371,065	\$1,330,455	\$680,511	\$3,132,551
2021 Additions	-	-	9,393	27,394	-	-	36,787
<b>September 30, 2021</b>	<b>\$254,939</b>	<b>\$220,078</b>	<b>\$284,896</b>	<b>\$398,459</b>	<b>\$1,330,455</b>	<b>\$680,511</b>	<b>\$3,169,338</b>
<b>ACCUMULATED DEPRECIATION:</b>							
December 31, 2019	\$(88,020)	\$(61,896)	\$(173,461)	\$(246,583)	\$(44,349)	\$(22,358)	\$(636,667)
Changes in 2020	(32,896)	(33,546)	(29,302)	(37,345)	(133,046)	(68,051)	(334,186)
December 31, 2020	\$(120,916)	\$(95,442)	\$(202,763)	\$(283,928)	\$(177,395)	\$(90,409)	\$(970,853)
Changes in 2021	(20,104)	(19,700)	(17,424)	(22,688)	(99,784)	(51,038)	(230,738)
<b>September 30, 2021</b>	<b>\$(141,020)</b>	<b>\$(115,142)</b>	<b>\$(220,187)</b>	<b>\$(306,616)</b>	<b>\$(277,179)</b>	<b>\$(141,447)</b>	<b>\$(1,201,591)</b>
<b>CARRYING AMOUNT</b>							
December 31, 2019	\$162,040	\$158,182	\$93,303	\$124,482	\$1,286,106	\$658,153	\$2,482,266
December 31, 2020	\$134,023	\$124,636	\$72,740	\$87,137	\$1,153,060	\$590,102	\$2,161,698
<b>September 30, 2021</b>	<b>\$113,919</b>	<b>\$104,936</b>	<b>\$64,709</b>	<b>\$91,843</b>	<b>\$1,053,276</b>	<b>\$539,064</b>	<b>\$1,967,747</b>

## 12. Intangible Assets

	New Product Dossier and Filing Costs	Product Licenses and Rights	New Product Development	Trademarks and Patents	Trade Certifications	Total
<b>COST:</b>						
December 31, 2019	\$1,502,207	\$893,020	\$71,950	\$92,786	\$3,936	\$2,563,899
2020 Additions	29,851	60,000	60,549	10,280	-	160,680
December 31, 2020	\$1,532,058	\$953,020	\$132,499	\$103,066	\$3,936	\$2,724,579
2021 Additions	4,090	-	-	-	-	4,090
<b>September 30, 2021</b>	<b>\$1,536,148</b>	<b>\$953,020</b>	<b>\$132,499</b>	<b>\$103,066</b>	<b>\$3,936</b>	<b>\$2,728,669</b>
<b>ACCUMULATED AMORTIZATION:</b>						
December 31, 2019	\$(54,103)	\$(297,794)	\$-	\$(13,121)	\$(796)	\$(365,814)
Changes in 2020	(87,395)	(81,513)	(1,504)	(5,031)	(793)	(176,236)
December 31, 2020	\$(141,498)	\$(379,307)	\$(1,504)	\$(18,152)	\$(1,589)	\$(542,050)
Changes in 2021	(64,870)	(40,914)	(5,180)	(4,949)	(562)	(116,475)
<b>September 30, 2021</b>	<b>\$(206,368)</b>	<b>\$(420,221)</b>	<b>\$(6,684)</b>	<b>\$(23,101)</b>	<b>\$(2,151)</b>	<b>\$(658,525)</b>
<b>ACCUMULATED IMPAIRMENT LOSSES:</b>						
December 31, 2019	\$(713,341)	\$(461,366)	\$-	\$-	\$-	\$(1,174,707)
Changes in 2020	-	-	-	-	-	-
December 31, 2020	\$(713,341)	\$(461,366)	\$-	\$-	\$-	\$(1,174,707)
Changes in 2021	-	-	-	-	-	-
<b>September 30, 2021</b>	<b>\$(713,341)</b>	<b>\$(461,366)</b>	<b>\$-</b>	<b>\$-</b>	<b>\$-</b>	<b>\$(1,174,707)</b>
<b>CARRYING AMOUNT</b>						
December 31, 2019	\$734,763	\$133,860	\$71,950	\$79,665	\$3,140	\$1,023,378
December 31, 2020	\$677,219	\$112,347	\$130,995	\$84,914	\$2,347	\$1,007,822
<b>September 30, 2021</b>	<b>\$616,439</b>	<b>\$71,433</b>	<b>\$125,815</b>	<b>\$79,965</b>	<b>\$1,785</b>	<b>\$895,437</b>

### New Product Dossier and Filing Costs

Cumulatively, the Company has incurred product dossier and filing costs of \$1,536,148 (December 31, 2020 – \$1,532,058) to date on several products. The filing costs incurred in respect of launched products are being amortized on a straight-line basis over their estimated finite useful lives based on marketability, ranging from 1 to 15 years.

In August 2012, BioSyent Pharma signed an exclusive Licensing and Distribution Agreement for the Aguettant System® of pre-filled syringes (“PFS”) in Canada, including the Atropine Sulphate PFS and Phenylephrine Hydrochloride PFS.

The Aguettant Agreement will end on December 31, 2021 and BioSyent has entered into Termination and Transition Agreements with Laboratoire Aguettant that transfer all responsibilities for Aguettant System® products in Canada to Laboratoire Aguettant. BioSyent will discontinue all commercialization efforts for Aguettant System® products in Canada effective January 1, 2022. The New Product Dossier and Filing Costs associated with these PFS products, launched in February 2015 and November 2016, respectively, have been fully amortized as of September 30, 2021.

On November 7, 2016, the Company entered into a License and Supply Agreement with a European partner to acquire the exclusive Canadian rights to use the product registration documentation of a women’s health pharmaceutical product and a license to sell, market and distribute this product in Canada under

the brand name Tibella®. On May 10, 2019, the Company received regulatory approval from Health Canada for the Tibella® product which was subsequently launched in Canada in July 2020. The Company has incurred \$466,123 in development costs related to this product. Such costs are included in intangible assets as New Product Dossier and Filing Costs and are being amortized on a straight-line basis over the 8-year estimated useful life of the product. In addition to an initial EUR 20,000 license fee upon signing this agreement, the Company is committed to certain annual license fee payments to its European partner contingent upon the future sales of the product (see Note 19).

In November 2019, the Company entered into a License and Exclusive Supply Agreement with AFT Pharmaceuticals Ltd (“AFT”) to acquire a license to market, sell and distribute a portfolio of pain management products in Canada. The Company launched the Combogesic® product in Canada in December 2020. The Company has directly incurred \$202,367 in development costs related to these products. Such costs are included in intangible assets as New Product Dossier and Filing Costs and are being amortized over the 15-year estimated useful life of the Combogesic® product. During the 15-year term of the License and Exclusive Supply Agreement, the Company is committed to purchase certain minimum quantities from AFT as well as certain royalty payments based on the net sales of the products in Canada (see Note 19).

For the nine months ended September 30, 2021, \$64,870 of amortization expense on New Product Dossier and Filing Costs (nine months ended September 30, 2020 - \$57,388) has been included in selling, general and administration expenses in the Company’s Consolidated Statements of Income and Comprehensive Income in respect of these assets (see Note 17).

### Product Licenses and Rights

Cumulatively, the Company has incurred costs related to the acquisition of product licenses and rights totalling \$953,020 (December 31, 2020 - \$953,020).

On August 18, 2015, the Company entered into a Distribution and Supply Agreement with Photocure ASA (the “Distribution and Supply Agreement”) to acquire the exclusive rights to market, promote, distribute and sell the Cysview® product in Canada including an exclusive right to use the Cysview® trademark and a license to use the patents associated with the product in Canada. The Company incurred costs totalling \$859,400 (December 31, 2020 - \$859,400) related to the acquisition and commercialization of Cysview®, which was launched in the Canadian market in November 2015.

BioSyent has entered into a Termination and Transition Agreement with Photocure ASA, that ends the Distribution and Supply Agreement effective December 31, 2021. On January 1, 2022, BioSyent will discontinue all commercialization efforts on Cysview® and return the Canadian rights for Cysview® to Photocure ASA. As of September 30, 2021, the Cysview® product license intangible asset has a carrying value of \$nil.

On October 1, 2020, the Company entered into an exclusive License and Supply Agreement to acquire the exclusive rights to distribute a women’s health product in Canada and a license of certain trademarks and technology related thereto. The product has not yet been launched by the Company and amortization of the asset has not yet commenced.

For the nine months ended September 30, 2021, \$40,914 of amortization expense on product licenses and rights (nine months ended September 30, 2020 - \$60,692) has been included in selling, general and administration expenses in the Company’s Consolidated Statements of Net Income and Comprehensive Income in respect of this asset (see Note 17).

### New Product Development

The Company has incurred cumulative new product development costs consisting of labour, laboratory and professional fees to date totalling \$132,499 (December 31, 2020 - \$132,499) relating to the development of new products. The Company has commenced amortization of certain of these costs upon the completion of development. For the nine months ended September 30, 2021, \$5,180 of amortization expense (nine months ended September 30, 2020 - \$24,787) has been included in selling, general and administration expenses in the Company’s Consolidated Statements of Net Income and Comprehensive Income in respect of these development costs (see Note 17).

### Trademarks and Patents

The Company has incurred cumulative trademark and patent application and filing costs of \$103,066 (December 31, 2020 - \$103,066) relating to product registration application costs in various jurisdictions. These assets have finite lives and are being amortized on a straight-line basis over the terms of the respective trademarks and patents (ranging from 10 to 15 years). For the nine months ended September 30, 2021, \$4,949 of amortization expense (nine months ended September 30, 2020 - \$3,386) has been included in selling, general and administration expenses in the Company’s Consolidated Statements of Net Income and Comprehensive Income in respect of these assets (see Note 17).

### Trade Certifications

The Company has incurred legal and other costs in obtaining certain international trade certifications and permits totalling \$3,936 (December 31, 2020 - \$3,936). This asset is being amortized over its 5-year estimated useful life. For the nine months ended September 30, 2021, \$562 of amortization expense (nine months ended September 30, 2020 - \$618) has been included in selling, general and administration expenses in the Company’s Consolidated Statements of Comprehensive Income in respect of these development costs (see Note 17).

### 13. Loans Receivable

On December 8, 2016, the Board of Directors approved a Management Share Loan Program (“MSLP”) under which the Company offered one-time, secured loans to certain management personnel employed by the Company (each a “Borrower”) up to a maximum of fifty percent of each Borrower’s base annual salary for the sole purpose of their purchase of the Company’s issued and outstanding common shares at prevailing market prices through the facilities of the TSX Venture Exchange.

	Loans Receivable (\$)
Balance, December 31, 2019	588,467
Accrued Interest	8,865
Balance, December 31, 2020	597,332
Accrued Interest	4,468
<b>Balance, September 30, 2021</b>	<b>601,800</b>
<b>Current portion, September 30, 2021</b>	<b>419,056</b>
<b>Non-current portion, September 30, 2021</b>	<b>182,744</b>
Current portion, December 31, 2020	-
Non-current portion, December 31, 2020	597,332

### 14. Contract Liability

The Company recognizes a contract liability based on its estimate of the amount of consideration it expects to refund to its customers, including consideration payable resulting from coupons and volume rebates. This contract liability is updated at the end of each period for any changes in circumstances.

The table below summarizes changes in the contract liability for the year ended December 31, 2020 and nine months ended September 30, 2021:

The Company advanced loan proceeds totalling \$391,500 on May 26, 2017, and a further \$175,000 on December 11, 2018, in accordance with the terms of the MSLP for the purchase of the Company’s common shares by the Borrowers.

Each MSLP participant’s loan (collectively, the “MSLP Participant Loans”) bears interest at a rate of 1% - 2% per annum and is secured by a pledge of the common shares purchased under the MSLP by the Borrowers. Interest receivable of \$4,468 was accrued on the loans for the nine months ended September 30, 2021 (nine months ended September 30, 2020 - \$8,835) and has been included in finance income on the Company’s Consolidated Statements of Net Income and Comprehensive Income.

The MSLP Participant Loans are repayable by the Borrowers upon any sale of pledged shares by the Borrower in proportion to the then outstanding loan principal balance plus accrued interest. The remaining MSLP Participant Loan principal plus accrued interest must be fully repaid by the Borrowers within five years from the date the loan proceeds were advanced (the “Maturity Date”), specifically, May 26, 2022 for loans advanced on May 26, 2017 and December 11, 2023 for loans advanced on December 11, 2018.

If a Borrower ceases to be employed by the Company prior to the end of the five-year Maturity Date, all outstanding loan obligations shall become due and payable on the 30th day following the date of termination. In addition, in the event of a default by the Borrower of the terms of the loan, the loan obligations will become due and payable immediately.

As the loans are full recourse loans, they have not been accounted for as stock-based compensation, but as financial instruments within the scope of IFRS 9, *Financial Instruments*.

	Contract Liability (\$)
Balance, December 31, 2019	99,141
Estimated variable consideration	680,797
Settlement of variable consideration	(533,814)
<b>Balance, December 31, 2020</b>	<b>246,124</b>
Estimated variable consideration	147,295
Settlement of variable consideration	(160,602)
<b>Balance, September 30, 2021</b>	<b>232,817</b>



## 15. Lease Liability

The Company leases its head office space in Mississauga, Ontario, Canada. The Company's current office lease commenced on September 1, 2019 and extends to August 31, 2029. The Company has an option to extend this lease beyond the 10-year non-cancellable term for a further term of 5 years. As per IFRS 16 *Leases*, the Company has recognized a right-of-use asset in respect of this office lease based on a 10-year lease term (see Note 11).

The Company has also recognized a lease liability for this office lease based on a weighted average incremental borrowing rate of 5.20%. The carrying amount of the Company's lease liability for this office lease is summarized in the table below:

	Lease Liability (\$)
<b>Balance, December 31, 2019</b>	<b>1,853,114</b>
Interest expense	92,942
Payments	(237,195)
<b>Balance, December 31, 2020</b>	<b>1,708,861</b>
Interest expense	64,503
Payments	(177,896)
<b>Balance, September 30, 2021</b>	<b>1,595,468</b>
<b>Current portion, September 30, 2021</b>	<b>158,401</b>
<b>Long-term portion, September 30, 2021</b>	<b>1,437,067</b>
<b>Current portion, December 31, 2020</b>	<b>151,949</b>
<b>Long-term portion, December 31, 2020</b>	<b>1,556,912</b>

The Company's future undiscounted lease payments under this lease agreement are as follows:

Fiscal Year	Lease Payments
2021	\$ 59,299
2022	\$ 238,952
2023	\$ 242,466
2024	\$ 242,466
2025	\$ 245,980
Beyond next 5 fiscal years	\$ 927,696
<b>Total</b>	<b>\$ 1,956,859</b>

Not included in the lease liability, the Company incurred occupancy costs, net of recoveries, related to its office leases of \$89,002 for the nine months ended September 30, 2021 (nine months ended September 30, 2020 - \$91,192) which have been included in selling, general and administration expenses in the Company's Consolidated Statements of Net Income and Comprehensive Income.

## 16. Share Capital

### a. Authorized

The authorized share capital of the Company consists of 100,000,000 common shares without par value and 25,000,000 preferred shares without par value. The holders of the preferred shares as a class shall not be entitled to receive notice of, to attend or to vote at any meeting of the shareholders of the Company.

b. Issued and outstanding common shares

	Number of Issued Common Shares	Number of Treasury Shares	Number of Outstanding Common Shares	Amount
<b>Balance, December 31, 2019</b>	13,530,445	-	13,530,445	\$7,179,617
Options exercised	1,196	-	1,196	14,718
Shares repurchased under NCIB and cancelled (d)	(594,275)	-	(594,275)	(308,089)
Shares purchased for RSU Plan Trust and held in Treasury (e)	-	(132,200)	(132,200)	(493,818)
<b>Balance, December 31, 2020</b>	12,937,366	(132,200)	12,805,166	\$6,392,428
Options exercised (c)	1,182	-	1,182	16,086
Shares repurchased under NCIB and cancelled (d)	(79,700)	-	(79,700)	(39,601)
Shares purchased for RSU Plan Trust and held in Treasury (e)	-	(69,300)	(69,300)	(527,179)
<b>Balance, September 30, 2021</b>	12,858,848	(201,500)	12,657,348	\$5,841,734

c. Options exercised

During the nine months ended September 30, 2021, 1,182 common shares were issued against options exercised (nine months ended September 30, 2020 – 430 common shares) for total proceeds of \$8,090 (nine months ended September 30, 2020 – \$2,666) and \$7,996 in fair value was transferred from contributed surplus to share capital (nine months ended September 30, 2020 – \$2,625).

d. Normal Course Issuer Bid (NCIB)

Pursuant to the policies of the TSX Venture Exchange, the Company may be permitted from time to time to repurchase its own common shares for cancellation under a NCIB. The policies of the TSX Venture Exchange permit an issuer, upon the approval of the TSX Venture Exchange, to purchase by normal market purchases up to 2% of a class of its own shares in a given 30-day period up to a maximum, in a 12-month period, of the greater of 5% of the outstanding shares or 10% of the Public Float, as such term is defined in the policies of the TSX Venture Exchange.

On December 11, 2019, the Company announced that the TSX Venture Exchange had accepted its renewal of the NCIB, pursuant to which the Company would be permitted to purchase up to 800,000 of its own common shares for cancellation over a further 12-month period commencing on December 17, 2019 and ending on December 16, 2020. Purchases of shares by the Company under the NCIB were made through the facilities of the TSX Venture Exchange or alternative Canadian trading systems at the market price of the shares at the time of acquisition.

During the year ended December 31, 2020, the Company repurchased 594,275 of its common shares for an aggregate price of \$2,503,810 and incurred costs of \$8,444 related to the repurchase of these shares. The Company's retained earnings were reduced by \$2,204,165 upon the repurchase of these shares, representing the excess of the aggregate repurchase price over the reduction in share capital of \$308,089.

On December 11, 2020, the Company announced that the TSX Venture Exchange had accepted its renewal of the NCIB, pursuant to which the Company would be permitted to purchase up to 950,000 of its own common shares for cancellation over a further 12-month period commencing on December 17, 2020 and ending on December 16, 2021. Purchases of shares by the Company under the NCIB are made through the facilities of the TSX Venture Exchange or alternative Canadian trading systems at the market price of the shares at the time of acquisition.

During the nine months ended September 30, 2021, the Company repurchased 79,700 of its common shares for an aggregate price of \$561,621 and incurred costs of \$797 related to the repurchase of these shares. The Company's retained earnings were reduced by \$522,817 upon the repurchase of these shares, representing the excess of the aggregate repurchase price over the reduction in share capital of \$39,601.

e. During the year ended December 31, 2020, the Company purchased 132,200 of its common shares pursuant to its Restricted Share Unit ("RSU") Plan (see Note 16(g)) for an aggregate purchase price of \$493,818.

During the nine months ended September 30, 2021, the Company purchased 69,300 of its common shares pursuant to its Restricted Share Unit ("RSU") Plan (see Note 16(g)) for an aggregate purchase price of \$527,179.

201,500 treasury shares are held in trust as of September 30, 2021 (December 31, 2020 – 132,200 treasury shares) for future settlement of vested RSUs granted to employees, senior management, and directors of the Company.

f. There are nil preferred shares outstanding as of September 30, 2021 (December 31, 2020 – nil).

g. Share-Based Payments

#### Restricted Share Unit ("RSU") Plan

The Board adopted a Restricted Share Unit Plan on March 4, 2020, which was approved by shareholders on May 27, 2020 and subsequently approved by the TSX Venture Exchange. The

RSU Plan was established as a vehicle by which equity-based incentives may be granted to eligible employees, consultants, directors and officers of the Company to recognize and reward their contributions to the long-term success of the Company including aligning their interests more closely with the interests of the Company's shareholders. The RSU Plan is a fixed plan which reserves for issuance a maximum of 800,000 common shares of the Company.

On March 31, 2020, a total of 129,125 RSUs were granted to certain employees, senior management, and directors of the Company with a fair value of \$3.61 per unit, being the grant date closing (TSX Venture Exchange) market price per share. Certain of these units shall vest fully in three years' time on March 31, 2023 and certain of these units shall vest quarterly in three years' time on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023.

On March 19, 2021, a total of 67,252 RSUs were granted to certain employees, senior management, and directors of the Company with a fair value of \$7.30 per unit, being the grant date closing (TSX Venture Exchange) market price per share. Certain of these units shall vest fully in three years' time on March 19, 2024 and certain of these units shall vest quarterly on March 31, 2024, June 30, 2024, September 30, 2024, and December 31, 2024.

During the nine months ended September 30, 2021, the Company recorded net share-based payment expense of \$187,904 (nine months ended September 30, 2020 - \$73,904) relating to RSUs granted to employees, directors, officers and advisors under the RSU Plan, which is included in selling, general and administration expenses in the Consolidated Statements of Net Income and Comprehensive Income.

As at September 30, 2021, there were 194,345 RSUs outstanding (December 31, 2020 - 129,125), as shown below:

	September 30, 2021		December 31, 2020	
	Number of RSUs	Weighted average grant price	Number of RSUs	Weighted average grant price
Outstanding, beginning of period	129,125	\$3.61	-	-
Granted	67,252	\$7.30	129,125	\$3.61
Forfeited	(2,032)	\$4.96	-	-
Outstanding, end of period	194,345	\$4.87	129,125	\$3.61

The weighted-average remaining contractual life of the 194,345 RSUs outstanding at September 30, 2021 is 2.14 years (December 31, 2020 - 2.68 years).

### Incentive Stock Option Plan

On March 11, 2014, the Board approved an incentive stock option plan (the "SOP") which was adopted by the shareholders of the Company on June 13, 2014. The Board approved an amended SOP on March 4, 2020 which was approved by shareholders on May 27, 2020 and re-approved on May 26, 2021. The purpose of the SOP is to assist the Company in attracting, retaining and motivating directors, officers, employees and other persons who provide ongoing services to the Company and its affiliates and to closely align the personal interests of such participants with those of the Company's shareholders, by providing them with

the opportunity to acquire common shares of the Company, and thereby a proprietary interest in the Company and its subsidiaries, through the exercise of share purchase options.

No options were granted by the Company during the year ended December 31, 2020.

No options were granted by the Company during the nine months ended September 30, 2021.

During the nine months ended September 30, 2021, the Company recorded net share-based payment expense of \$58,200 (nine months ended September 30, 2020 - \$122,083) relating to previous option grants to employees, directors, officers and advisors under the SOP, which is included in selling, general and administration expenses in the Consolidated Statements of Net Income and Comprehensive Income.

As at September 30, 2021, there were 172,657 options outstanding (December 31, 2020 - 173,839), as shown below:

	September 30, 2021		December 31, 2020	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Outstanding, beginning of period	173,839	\$8.32	177,512	\$8.30
Granted	-	-	-	-
Expired or forfeited	(101)	\$10.97	(2,477)	\$7.78
Exercised	(1,182)	\$6.84	(1,196)	\$6.20
Outstanding, end of period	172,556	\$8.33	173,839	\$8.32

Of the total number of options outstanding as of September 30, 2021, options totalling 146,857 have vested and are exercisable by the option holders (December 31, 2020 – 124,120). These exercisable options have a weighted average exercise price of \$8.27 (December 31, 2020 – \$8.21).

The weighted-average remaining contractual life of the 172,556 (December 31, 2020 – 173,839) options outstanding is 5.52 years (December 31, 2020 – 6.26 years) and the range of exercise prices for these options is \$6.20 – \$10.97 (December 31, 2020 – \$6.20 – \$10.97).

1,182 options were exercised during the nine months ended September 30, 2021 (nine months ended September 30, 2020 – 430 options). The weighted average share price on the date of exercise of options exercised during the nine months ended September 30, 2021 was \$7.89 (nine months ended September 30, 2020 – \$7.35).

### **Employee Share Purchase Plan**

On January 1, 2017, the Company introduced an Employee Share Purchase Plan (“ESPP”). Under the ESPP, eligible BioSyent employees, including certain key management personnel, are permitted to contribute up to a maximum of 10 per cent of their gross base salary to purchase the Company’s common shares in the open market through the facilities of the TSX Venture Exchange. The contributions are matched by the Company up to a maximum of 2.5 per cent of the applicable employee’s gross base salary.

During the nine months ended September 30, 2021, the Company recorded share-based payment expense of \$38,989 (nine months ended September 30, 2020 – \$19,908) relating to the Company’s contributions to the ESPP for the purchase of common shares on behalf of participating employees. Company and employee contributions to the ESPP were temporarily suspended between April 1, 2020 and March 31, 2021.

## 17. Expenses by Nature

The expenses on the Consolidated Statements of Comprehensive Income have been grouped by function to focus reader attention on the macro movements in cost from period to period while giving the reader an option to see the detail of expenses according to their nature, which are included below:

	Three months ended September 30,		Nine months ended September 30,	
	2021	2020	2021	2020
<b>Cost of goods sold</b>	\$1,433,239	\$1,277,645	\$4,583,301	\$3,581,708
<b>Selling and marketing</b>	\$1,930,870	\$2,019,647	\$7,078,906	\$5,154,586
Advertising, Promotion and Selling Costs	1,011,274	1,042,293	4,304,866	2,601,894
Employee Costs	739,151	878,499	2,210,654	2,121,938
Logistics, Quality Control & Regulatory	172,785	96,710	533,943	417,782
Share-based Payments (Note 16)	7,660	2,145	29,443	12,972
<b>General and administration</b>	\$1,123,328	\$1,200,186	\$3,872,076	\$3,763,938
Employee Costs	675,892	867,141	2,123,475	2,137,368
Corporate Expenses	81,600	59,971	496,755	526,214
Professional Fees	90,707	44,317	245,438	164,718
Share-based Payments (Note 16)	96,118	67,767	255,650	202,923
Depreciation - Property and Equipment (Note 11)	77,310	82,649	230,738	250,171
Information Technology	55,896	39,257	150,420	114,356
Amortization - Intangible Assets (Note 12)	26,991	56,304	116,475	146,871
Research and Development	86,392	13,685	116,167	219,061
Insurance	33,378	26,503	98,516	78,133
Net Foreign Exchange Losses (Gains)	(100,956)	(57,408)	38,442	(75,877)
<b>New business development costs</b>	\$13,570	\$30,143	\$67,911	\$59,010
<b>Finance costs</b>	\$21,248	\$23,134	\$64,503	\$70,286
Interest expense - lease liability (Note 15)	21,248	23,134	64,503	70,286
<b>Finance income</b>	\$ (31,434)	\$ (81,566)	\$ (99,018)	\$ (224,537)
Interest Income	(31,434)	(64,856)	(99,018)	(207,827)
Foreign Exchange Gains - Investing	-	(16,710)	-	(16,710)

## 18. Earnings per Share

The following table reconciles the numerator and denominator for the calculation of basic and diluted earnings per share:

	Three months ended September 30,		Nine months ended September 30,	
	2021	2020	2021	2020
<b>Numerator</b>				
Net income attributable to common shareholders	\$1,721,320	\$955,909	\$4,403,762	\$3,129,633
<b>Denominator</b>				
Basic				
Weighted average number of shares outstanding	12,669,586	12,808,287	12,730,752	13,061,099
Effect of dilutive securities	182,398	130,557	182,544	119,056
Diluted				
Weighted average number of shares outstanding	12,851,984	12,938,844	12,913,296	13,180,155
<b>Basic earnings per share</b>	\$0.136	\$0.075	\$0.346	\$0.240
<b>Diluted earnings per share</b>	\$0.134	\$0.074	\$0.341	\$0.237

## 19. Contingencies

### Litigations

From time to time, the Company may be exposed to claims and legal actions in the normal course of business. As at September 30, 2021, the Company was not aware of any litigation or threatened claims either outstanding or pending.

### Women's Health Product License and Supply Agreement

Under the terms of the November 7, 2016 License and Supply Agreement between the Company and its European partner in respect of the Tibella® women's health pharmaceutical product (see Note 12), the Company will make annual license fee payments to its European partner in each of the first four years of the Agreement equal to 1% of the Company's net sales of the product in Canada. For the nine months ended September 30,

2021, such fees for the period have been expensed and included in the Company's Consolidated Statements of Net Income and Comprehensive Income.

### Pain Management Products License and Exclusive Supply Agreement

Under the terms of the November 25, 2019 License and Exclusive Supply Agreement, the Company is required to make royalty payments to AFT Pharmaceuticals based on net sales of the pain management products in Canada and contingent on the market share of competing products in Canada over the 15-year term of the agreement. The royalty rates range from 0% to 6.5% on net sales of one product formulation and from 0% to 12.5% on net sales of another product formulation. For the nine months ended September 30, 2021, such fees for the period have been expensed and included in the Company's Consolidated Statements of Net Income and Comprehensive Income.

## 20. Commitments

### Office Lease

The Company's current office lease agreement commenced on September 1, 2019 and extends to August 31, 2029 (see Note 15).

The Company's undiscounted minimum future rental payments and estimated occupancy costs (including certain operating costs and realty taxes) for the next five fiscal years under this lease agreement are approximately as follows:

Fiscal Year	Rent and Occupancy Costs
2021	\$ 91,610
2022	\$ 368,197
2023	\$ 371,711
2024	\$ 371,711
2025	\$ 375,225
Beyond Next 5 Fiscal Years	\$ 1,401,596
<b>Total</b>	<b>\$ 2,980,050</b>

## Purchase Commitments

In the normal course of business, the Company has minimum purchase commitments with certain suppliers.

## 21. Related Party Transactions

### Key Management Personnel Compensation

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company and/or its subsidiaries, directly or indirectly.

The table below summarizes compensation for key management personnel of the Company for the three and nine months ended September 30, 2021 and 2020:

	Three months ended September 30,		Nine months ended September 30,	
	2021	2020	2021	2020
Number of Key Management Personnel	6	6	6	6
Salary, Benefits, and Bonus	\$315,443	\$310,885	\$943,254	\$932,582
Share-Based Payments	\$42,042	\$40,333	\$161,394	\$123,007

During the nine months ended September 30, 2021, the Company recorded share-based payment expense of \$161,394 (nine months ended September 30, 2020 - \$123,007) related to the amortization of RSUs and the vesting of options granted to key management personnel under the Company's RSU Plan and SOP as well as the Company's contributions to the ESPP for the purchase of common shares on behalf of participating key management personnel.

### Transactions with Directors

During the nine months ended September 30, 2021, the Company paid cash fees to its directors in the amount of \$81,984 (nine months ended September 30, 2020 - \$43,672) and recorded share-based payments expense for accounting purposes of \$26,485 (nine months ended September 30, 2020 - \$13,072) related to the amortization of RSUs and the vesting of options granted to directors under the Company's RSU Plan and SOP.

## 22. Capital Disclosures

For capital management purposes, the Company defines capital as its shareholders' equity that includes share capital, contributed surplus, cumulative translation adjustment and retained earnings.

The amounts included in the Company's capital for the relevant years are as follows:

September 30, 2021	\$30,332,390
December 31, 2020	\$26,795,956

The Company's principal objectives in managing capital are:

- to ensure that it will continue to operate as a going concern;
- to be flexible in order to take advantage of contract and growth opportunities that are expected to provide satisfactory returns to its shareholders;
- to maintain a strong capital base in order to maintain customers, investors, creditors and market confidence; and

- to provide an adequate rate of return to its shareholders.

The Company manages and adjusts its capital structure in light of changes in economic conditions.

In order to maintain or adjust its capital structure, the Company may issue debt or new shares. Financing decisions are generally made on a specific transaction basis and depend on such things as the Company's needs, capital markets and economic conditions at the time of the transaction. Management reviews its capital management approach on an ongoing basis and believes that this approach is reasonable, given the size of the Company.

The Company does not have any externally imposed capital compliance requirements at September 30, 2021. There were no changes in the Company's approach to capital management during the period.

## 23. Credit Facilities

The Company has credit facilities available with Royal Bank of Canada totalling \$3,090,000, including a revolving demand credit facility of \$1,500,000, which has not been utilized as of September 30, 2021, a foreign exchange facility of \$1,500,000, and credit card facilities totalling \$90,000. The revolving demand credit facility bears interest at a variable rate of Royal Bank prime plus 0.75% and has been secured with a General Security Agreement constituting a first ranking security interest of the Bank in the

Company's property. The Company is subject to maintaining certain financial covenants if the demand credit facility is drawn upon.

## 24. Taxes

The Company computes an income tax provision in each of the jurisdictions in which it operates. Actual amounts of income tax expense only become final upon filing and acceptance of the tax return by the relevant authorities, which occur subsequent to the issuance of the financial statements.

Additionally, estimation of income taxes includes evaluating the recoverability of deferred tax assets based on an assessment of the ability to use the underlying future tax deductions before they expire against future taxable income.

The assessment is based upon existing tax laws and estimates of future taxable income. To the extent estimates differ from the final tax return, earnings would be affected in a subsequent period. The operations are subject to income tax rates of 26.5% (2020 – 26.5%) in the Canadian jurisdiction, 21.0% (2020 – 21.0%) in the U.S. jurisdiction, and 4.0% (2020– 2.5%) in the Barbados jurisdiction.

## 25. Segment Reporting

A segment is a component of the Company:

- i. that engages in business activities from which it may earn revenue and incur expenses;
- ii. whose operating results are reviewed by the board of directors; and
- iii. for which discrete financial information available.

Though the Company has a legacy business in biologically and health friendly insecticides, management of the Company is primarily focused on growing the pharmaceutical business and does not account for administrative overhead separately for the insecticide business. Consequently, the Company recognizes one business segment for all of its operations.

The revenue breakdown by business is provided below:

- a. for both the pharmaceutical and insecticide business; and
- b. for both Canadian and international jurisdictions

	Three months ended September 30,		Nine months ended September 30,	
	2021	2020	2021	2020
<b>Canada</b>				
Pharmaceutical Business	\$6,409,809	\$5,470,569	\$19,313,894	\$15,842,030
Insecticide Business	179,225	175,486	608,803	422,856
<b>Total Canada</b>	<b>\$6,589,034</b>	<b>\$5,646,055</b>	<b>\$19,922,697</b>	<b>\$16,264,886</b>
<b>International Jurisdictions</b>				
Pharmaceutical Business - Middle East	-	\$6,306	\$1,305,317	\$168,471
Insecticide Business - United States	101,385	119,378	171,548	172,483
<b>Total International Jurisdictions</b>	<b>\$101,385</b>	<b>\$125,684</b>	<b>\$1,476,865</b>	<b>\$340,954</b>
<b>Total Revenue</b>	<b>\$6,690,419</b>	<b>\$5,771,739</b>	<b>\$21,399,562</b>	<b>\$16,605,840</b>

Non-Current Assets consist of equipment, intangible assets, loans receivable, and deferred tax asset. As indicated in the table below, Non-Current Assets are located in Canada and international jurisdictions.

	September 30, 2021	December 31, 2020
Canada	\$3,037,904	\$3,703,260
United States	-	20,040
Barbados	74,082	74,033
<b>Total Non-current Assets</b>	<b>\$3,111,986</b>	<b>\$3,797,333</b>



---

## Corporate Information

### Registered Office

Suite 402  
2476 Argentia Road  
Mississauga, Ontario, Canada L5N 6M1  
Telephone 905.206.0013  
Facsimile 905.206.1413  
Email [info@biosyent.com](mailto:info@biosyent.com)  
Website [www.biosyent.com](http://www.biosyent.com)

### Board of Directors

#### Larry Andrews

Ontario, Canada

#### Joseph Arcuri

Ontario, Canada

#### Sara Elford

British Columbia, Canada

#### René C. Goehrum (Chair)

Ontario, Canada

#### Peter D. Lockhard (Lead Director)

Ontario, Canada

#### Stephen Wilton

Ontario, Canada

### Officers

#### René C. Goehrum

President and  
Chief Executive Officer

#### Robert J. March

Vice-President and  
Chief Financial Officer

### Registrar and Transfer Agent

#### Computershare Trust Company Canada

100 University Avenue,  
Toronto, Ontario, M5J 2Y1  
Canada

### Auditors

#### MNP LLP

Toronto, Ontario, Canada

### Solicitors

#### Wildeboer Dellelce LLP

Toronto, Ontario, Canada

#### Caravel Law

Toronto, Ontario, Canada

#### Harridyal Sodha & Associates

St. Michael, Barbados

### Banks

#### Royal Bank of Canada

Toronto, Ontario, Canada

#### Canadian Imperial Bank of Commerce

Toronto, Ontario, Canada

#### City National Bank

Los Angeles, California, USA

### Stock Listing

#### TSX Venture Exchange

Trading symbol: RX